Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737513 | 1.00 | MGLL (0.40) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL19176551 | 1.00 | MGLL (0.40) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL18469617 | 0.98 | MGLL (0.39) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL21108746 | 0.98 | MGLL (0.37) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL18897244 | 0.97 | MGLL (0.36) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL20216152 | 0.94 | MGLL (0.38) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL18857274 | 0.94 | MGLL (0.38) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL22420047 | 0.87 | MGLL (0.40) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL20216162 | 0.85 | MGLL (0.37) | MGLLPTGS1PTGS2FAAHCA1 | |
| SCHEMBL21109437 | 0.84 | MGLL (0.38) | MGLLPTGS1PTGS2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | MGLL 2774/4885PTGS1 2500/4885PTGS2 2882/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MGLL 3812/4885PTGS1 2252/4885PTGS2 1705/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MGLL 616/4885PTGS1 3720/4885PTGS2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.